GSK-DB2116134

Study Sponsor: GSK

Study Title

DB2116134: A Randomized, Multi-center, Double-blind, Double-dummy, Parallel Group Study to Evaluate the Efficacy and Safety of Umeclidinium bromide/Vilanterol Compared with Fluticasone propionate/Salmeterol Over 12 weeks in Subjects with COPD

Medicine or Vaccine (generic name)

umeclidinium bromide/vilanterol

Sponsor Identification Number

DB2116134

Trial Registry Identification Number(#'s)

NCT01822899 2012-000524-18

Medical Condition

Pulmonary Disease, Chronic Obstructive

Phase

Phase 3

Link to study details on the GSK Clinical Study Register

https://www.gsk-studyregister.com/en/trial-details/?id=116134

Link to study details on ClinicalTrials.gov (if available)

http://clinicaltrials.gov/show/NCT01822899

Link to study details on EudraCT (if available)

https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000524-18

Datasets and Documents Available for this Study

Raw dataset	Annotated case report form	Dataset specifications	Protocol with any amendments
Analysis-ready dataset	Reporting and analysis plan	Clinical study report	Ready to Share

Additional information about the data and documents available for this study

Date Added to this Site

July 2016